Johnson & Johnson $JNJ Stake Lowered by Fifth Third Bancorp

Fifth Third Bancorp lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 0.8% in the third quarter, HoldingsChannel reports. The firm owned 1,927,920 shares of the company’s stock after selling 16,042 shares during the period. Johnson & Johnson comprises about 0.8% of Fifth Third Bancorp’s portfolio, making the stock its 21st largest holding. Fifth Third Bancorp’s holdings in Johnson & Johnson were worth $510,397,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Artemis Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 44.7% in the 3rd quarter. Artemis Wealth Advisors LLC now owns 2,315 shares of the company’s stock worth $613,000 after purchasing an additional 715 shares during the last quarter. Endeavor Private Wealth Inc. raised its stake in shares of Johnson & Johnson by 4.0% in the 3rd quarter. Endeavor Private Wealth Inc. now owns 2,577 shares of the company’s stock valued at $682,000 after purchasing an additional 100 shares in the last quarter. Banyan Capital Management Inc. bought a new position in shares of Johnson & Johnson during the third quarter worth about $703,000. CFM Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 3.9% during the third quarter. CFM Wealth Partners LLC now owns 2,127 shares of the company’s stock worth $563,000 after purchasing an additional 80 shares during the last quarter. Finally, Smith Partners Wealth Management LLC lifted its position in shares of Johnson & Johnson by 28.0% during the third quarter. Smith Partners Wealth Management LLC now owns 1,963 shares of the company’s stock worth $520,000 after purchasing an additional 430 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.1%

Johnson & Johnson stock opened at $280.52 on Thursday. The firm’s 50-day moving average is $266.67 and its 200-day moving average is $249.23. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a 1 year low of $193.07 and a 1 year high of $283.25. The company has a market cap of $675.29 billion, a P/E ratio of 42.50, a PEG ratio of 2.78 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the prior year, the firm earned $2.80 EPS. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is presently 81.21%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a report on Friday, October 16th. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Tuesday, September 29th. UBS Group set a $270.00 target price on Johnson & Johnson in a research report on Wednesday, October 14th. Johnson Rice lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Finally, Sanford C. Bernstein set a $270.00 price target on Johnson & Johnson in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $275.92.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.16% of the company’s stock.

Recent Johnson & Johnson Headlines

Here are a few of the latest headlines about JNJ:

• Positive Sentiment: J&J reported that a second pivotal Phase 3 trial of CAPLYTA met its primary and key secondary endpoints for bipolar I mania, with symptom improvement seen as early as Day 3. The two positive trials support a planned U.S. FDA submission, adding a potential growth opportunity. Reuters article
• Neutral Sentiment: J&J shares have risen substantially in recent years, prompting questions about whether expected cash flows justify the valuation; this could limit further gains if expectations are already reflected in the stock. Separately, a State Street health-care ETF sold J&J shares while reducing all of its holdings, which does not appear to be a company-specific signal. Valuation article
• Negative Sentiment: A Massachusetts jury awarded $3.3 million, including interest, to a family in a mesothelioma case tied to J&J talc-based baby powder. The award adds to the company’s ongoing talc litigation exposure. Verdict announcement

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.